Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: drdan who wrote (1931)	6/27/1998 1:16:00 AM
From: Andrew H	Read Replies (1) \| Respond to of 5402

>>Andrew, could you please tell us why it is so important to know the specific timetable for the applications. As long as the drug gets thru Phase One testing without any surprises about toxicity, pharm firms will be falling over themselves to buy into this company<< I don't remember saying it was so important to know the specific timetable for the applications. I was more concerned about the specific applications begin sought for approval. However, it is big assumption that"as long as the drug gets through P1 without any surprises about toxicity, pharms will be falling overthemselves to buy this company." That is merely your opinion of the situation. There is no evidence of this whatsoever, is there? If you can provide such evidence, I would love to see it. Many companies have gotten blood substitute products through P1 without having been bought out by a large pharm. These products later failed in P2 and P3 trials.

To: drdan who wrote (1931)	6/27/1998 9:28:00 AM
From: Mr. Forthright	Read Replies (3) \| Respond to of 5402

I think you are way to optimistic and are making statements that need to be clarified: <<As long as the drug gets thru Phase One testing without any surprises about toxicity, pharm firms will be falling over themselves to buy into this company.>> How can you say that? I know biotech companies in Phase 2b and/or 3 that have yet to sign up deals with big pharma. Also the risks of failure after Phase 1 are still extremely high. It is the nature of the business. SGNC may have the right scientific approach and may eventually get approved but that is years away and trust me the odds of you still being on the Internet promoting SGNC everyday for the next 5 years are very low: you will get bored with that long before it gets anywhere near approval. The problem I have with your post is that to the unsophisticated investor you may look like you know what you are talking about. To me, who has financed several biotech firms over the years, you clearly appear to be a neophyte. I wouldn't want small investors to get the wrong impression with respect to your statement.

To: drdan who wrote (1931)	6/27/1998 9:46:00 AM
From: Striyker	Respond to of 5402

drdan, honest question here. I don't know anything about pharm firms, but can we get one or two company names that might be interested in PHER-O2 and contact there CEO's, to get there take on SGNC? I don't know if they would be willing to comment on whether or not they would buy in to SGNC, but would be interesting to see what they have to say. Maybe you or chirodoc could call, since you have the most knowledge and find out what they would be looking for in SGNC before they bought in and what kind of time frame we could be looking at. AIMO, Striyker